Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in Asia: A Non-interventional Study

简要总结

主要结局

次要结局

• Healthcare resource(after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later)
• Adverse events rates in the different AF risk factor categories(after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later)
• Adjudicated symptomatic thromboembolic events(after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later)
• Non-major bleeding, collected as SAEs or non-serious AEs and defined as all bleeding events that do not fall in the category of major bleedings(after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later)
• Persistence with rivaroxaban treatment measured as percentage of patients on rivaroxaban treatment at 1 year after start of study treatment(after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later)
• Reasons for switch of rivaroxaban treatment as per physician assessment during or at end of study(after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later)
• Treatment satisfaction as per patient assessment of rivaroxaban treatment by the physician at the final visit(after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later)
• Reasons for interruption of rivaroxaban treatment as per physician assessment during or at end of study(after 1 year or until 30 days after end of rivaroxaban therapy, whichever is later)